Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label evaluation of once-daily Exelon 10 cm2 patch in probable Alzheimer's disease
2007-001383-70Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Jun 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-001383-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001383-70.